Acoramidis hydrochloride is a small molecule commercialized by BridgeBio Pharma, with a leading Pre-Registration program in Familial Amyloid Cardiomyopathy. According to Globaldata, it is involved in 10 clinical trials, of which 6 were completed, 3 are ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of Acoramidis hydrochloride’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData

The revenue for Acoramidis hydrochloride is expected to reach an annual total of $1.15 bn by 2033 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Acoramidis hydrochloride Overview

BBP-265 (AG-10) is under development for the treatment of familial amyloid cardiomyopathy (ATTR-CM). The drug candidate is administered through oral route in the form of tablet. It acts by targeting transthyretin protein.

It was under development for the treatment of familial amyloid polyneuropathy (FAP/hereditary transthyretin amyloidosis) and amyloidosis.

BridgeBio Pharma Overview

BridgeBio Pharma (BridgeBio) is a commercial-stage biopharmaceutical company that develops drugs for genetic diseases and cancer. The company’s pipeline products include precision cardiorenal, mendelian, precision oncology and gene therapy. Its precision cardiorenal and mendelian drugs include acoramidis, encaleret, fosdenopterin, low-dose infigratinib, BBP-418 and BBP-671. BridgeBio’s precision oncology and gene therapy drugs include high-dose infigratinib, BBO-8520, BBP-398, PI3Ka, BBP-954, Pan-KRAS inhibitor, BBP-812, BBP-631 and AAV gene therapy. The company’s brands include TRUSELTIQ and NULIBRY. It works in partnership with academic partners and industrial partners. The company operates in Canada, the US, France, Germany, Switzerland and the UK, among others. BridgeBio is headquartered in Palo Alto, California, the US.

For a complete picture of Acoramidis hydrochloride’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 22 April 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.